Silicon Hills Capital

Anita C. Roberts serves as the firm's Founder and General Partner and is the sole named investment decision-maker. Her background spans US Army service as a commissioned officer and combat veteran, followed by careers in human resources, public relations, and angel investing. She also holds a Venture Capital Certificate from UC Berkeley's Haas School of Business through its executive education program. No other investment committee members, principals, or venture partners are publicly disclosed.

The firm's sourcing model relies on founder relationships and networks that exist outside the conventional venture referral pipeline. Because the investment thesis is built around underestimated founders — women, people of color, veterans, and LGBTQ+ entrepreneurs — many of the companies Roberts backs are not in routine rotation at traditional institutional seed funds. The firm's public materials do not describe a formal scout network, an accelerator partnership strategy, or a proprietary data-sourcing platform.

Silicon Hills Capital operates as a venture capital firm managed by a solo general partner. It is not a family office; the firm's website includes an investor contact page soliciting limited partners, which implies pooled third-party capital rather than a single-family balance sheet. The legal fund structure, fund size, and LP base are not publicly detailed.

The firm's stated strategy focuses exclusively on direct investments into early-stage operating companies at the Pre-Seed, Seed, and Series A stages. There is no public indication that Silicon Hills Capital makes fund-of-fund commitments, purchases secondary interests, or invests in other venture firms as a limited partner. The disclosed portfolio contains only direct operating-company positions.

The firm does not publish a formal negative sector screen. However, the portfolio composition and stated focus on consumer-facing, identity-aligned marketplaces and packaged goods — including Shop Latinx, Tradeblock, and Elite Sweets — suggests a de facto avoidance of enterprise software, deep tech, infrastructure, and life sciences. No biotech, SaaS, or hardware investments are listed among the disclosed positions.